Meet The CEO Making The Next Generation Of Gene Therapies Possible
11/16/2016 7:03:40 AM
How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success.
The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors as a means of delivery. CEVEC’s contribution is a platform that includes two technologies, CAP-Go for the tailor-made production of previously inaccessible recombinant proteins and CAP-GT for industrial scale production of lentiviral, adenoviral and AAV gene therapy vectors.
comments powered by